Law360 (April 15, 2019, 2:15 PM EDT) -- Drug development and delivery company Catalent on Monday agreed to buy private equity-backed Paragon Bioservices Inc. for $1.2 billion, in a deal steered by Fried Frank, Kirkland, Gordon Feinblatt and Latham.
The transaction sees New Jersey-headquartered Catalent Inc. buying Baltimore-based Paragon, which develops viral vectors for gene therapies, according to a statement. In Paragon, Catalent picks up a business that is expected to post more than $200 million in revenue this year.
John Chiminski, chair and CEO of Catalent, said in a statement that “Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.